- Home
- CAPR vs BH Comparison
CAPR vs BH Comparison
Compare CAPR & BH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- BH
- Stock Information
- Founded
- CAPR 2005
- BH 1934
- Country
- CAPR United States
- BH United States
- Employees
- CAPR N/A
- BH N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- BH Restaurants
- Sector
- CAPR Health Care
- BH Consumer Discretionary
- Exchange
- CAPR Nasdaq
- BH Nasdaq
- Market Cap
- CAPR 600.7M
- BH 681.4M
- IPO Year
- CAPR N/A
- BH N/A
- Fundamental
- Price
- CAPR $11.15
- BH $254.31
- Analyst Decision
- CAPR Strong Buy
- BH
- Analyst Count
- CAPR 6
- BH 0
- Target Price
- CAPR $41.67
- BH N/A
- AVG Volume (30 Days)
- CAPR 3.3M
- BH 32.3K
- Earning Date
- CAPR 05-13-2025
- BH 05-09-2025
- Dividend Yield
- CAPR N/A
- BH N/A
- EPS Growth
- CAPR N/A
- BH N/A
- EPS
- CAPR N/A
- BH N/A
- Revenue
- CAPR $17,363,588.00
- BH $367,698,000.00
- Revenue This Year
- CAPR $78.79
- BH N/A
- Revenue Next Year
- CAPR $158.07
- BH N/A
- P/E Ratio
- CAPR N/A
- BH N/A
- Revenue Growth
- CAPR N/A
- BH 0.85
- 52 Week Low
- CAPR $3.52
- BH $159.69
- 52 Week High
- CAPR $23.40
- BH $271.35
- Technical
- Relative Strength Index (RSI)
- CAPR 56.47
- BH 61.66
- Support Level
- CAPR $10.04
- BH $244.01
- Resistance Level
- CAPR $10.80
- BH $267.00
- Average True Range (ATR)
- CAPR 1.07
- BH 10.07
- MACD
- CAPR 0.20
- BH 0.48
- Stochastic Oscillator
- CAPR 87.16
- BH 65.59
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About BH Biglari Holdings Inc. Class B
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, Oil and Gas Operations. Company's restaurant operations include Steak n Shake and Western Sizzlin. Its insurance operations include First Guard, Southern Pioneer, and Biglari Reinsurance. Oil and gas operations include Southern Oil and Abraxas Petroleum. The Company also reports segment information for Maxim. The majority of revenue is derived from the Maxim Segment.